project id: TCGA-PRAD; case submitter id: TCGA-VN-A88Q; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.75; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.56; rna integrity number: 8.4; age at index: 60; days to birth: -22087; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1950; age at diagnosis: 22087; ajcc clinical m: M0; ajcc clinical t: T2a; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1366.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 1029; initial weight: 90.0; sample id: 5807f769-5be7-4d07-a415-033dabfacff2; sample submitter id: TCGA-VN-A88Q-01A; portion id: 249676f2-f91f-4a06-b769-2b6b2e0e1ddb; portion submitter id: TCGA-VN-A88Q-01A-11; slide id: 9ffef08d-3380-410a-8859-d0c6777cc42f; slide submitter id: TCGA-VN-A88Q-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 80.0; section location: TOP;